Recombinant bacillus Calmette-Guerin in urothelial bladder cancer immunotherapy: current strategies

被引：8
|
作者：
Wang, Yonghua [1 ]
Yang, Meng [1 ]
Yu, Qinchao [1 ]
Yu, Lun [1 ]
Shao, Shixiu [1 ]
Wang, Xinsheng [1 ]
机构：
[1] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266071, Peoples R China
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
bacillus Calmette-Guerin; BCG; immunotherapy; intravesical therapy; recombinant BCG; urothelial bladder cancer; TRANSITIONAL-CELL CARCINOMA; EXPRESSING PERTUSSIS TOXIN; GAMMA-INDUCING FACTOR; MYCOBACTERIUM-BOVIS; IFN-GAMMA; INTRAVESICAL THERAPY; DNA VACCINES; MITOMYCIN-C; TH1-STIMULATING CYTOKINES; PLUS INTERFERON-ALPHA-2B;
D O I：
10.1586/14737140.2015.961430
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bacillus Calmette-Guerin (BCG) has been used in the intravesical treatment of urothelial bladder cancer (UBC) for three decades. Despite its efficacy, intravesical BCG therapy is associated with some limitations such as side effects and BCG failure, which have inspired multiple ways to improve it. Recent advances have focused on recombinant BCG (rBCG) which provides a novel tactic for modification of BCG. To date, a number of rBCG strains have been developed and demonstrated to encourage efficacy and safety in preclinical and clinical studies. This review summarizes current rBCG strategies, concerns and future directions in UBC immunotherapy with an intention to encourage further research and eventually to inform clinical decisions.
引用
收藏
页码：85 / 93
页数：9
相关论文
共 50 条
  • [41] Re: History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success Story Reply
    不详
    [J]. JOURNAL OF UROLOGY, 2008, 180 (05): : 2255 - 2255
  • [42] Current status of tuberculosis and recombinant bacillus Calmette-Guerin vaccines
    Ohara, Naoya
    [J]. JOURNAL OF ORAL BIOSCIENCES, 2012, 54 (02): : 92 - 95
  • [43] Human gene polymorphism and response to Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer
    Chiong, Edmund
    Kesavan, Arshvin
    Mahendran, Ratha
    Chan, Yiong Huak
    Tan, Theresa M. C.
    Esuvaranathan, Kesavan
    [J]. JOURNAL OF UROLOGY, 2008, 179 (04): : 614 - 614
  • [44] HUMAN GENE POLYMORPHISM AND RESPONSE TO BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR SUPERFICIAL BLADDER CANCER
    Chiong, E.
    Kesavan, A.
    Mahendran, R.
    Chan, Y. H.
    Tan, T. M. C.
    Esuvaranathan, K.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 261 - 261
  • [45] Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guerin for Bladder Cancer
    Liu, Yuqing
    Lu, Jian
    Huang, Yi
    Ma, Lulin
    [J]. JOURNAL OF ONCOLOGY, 2019, 2019
  • [46] Human gene polymorphism and response to bacillus calmette-guerin immunotherapy for superficial bladder cancer
    Chiong, E.
    Mahendran, R.
    Esuvaranathan, K.
    Kesavan, A.
    Chan, Y. H.
    Tan, T. M. C.
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 : A292 - A292
  • [47] Emerging Immunotherapy Options for bacillus Calmette-Guerin Unresponsive Nonmuscle Invasive Bladder Cancer
    Meng, Maxwell V.
    Gschwend, Juergen E.
    Shore, Neal
    Grossfeld, Gary D.
    Mostafid, Hugh
    Black, Peter C.
    [J]. JOURNAL OF UROLOGY, 2019, 202 (06): : 1111 - 1119
  • [48] Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma
    Cugati, Sudha
    Gilhotra, Jagjit Singh
    Lake, Stewart
    Gordon, David L.
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 (05): : 494 - 495
  • [49] Nonmuscle invasive urothelial cancer- Bacillus Calmette-Guerin instillation or checkpoint inhibitor immunotherapy?
    Broenimann, Stephan
    Shariat, Shahrokh F.
    Hassler, Melanie R.
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (04) : 319 - 323
  • [50] Strategies for Optimizing Bacillus Calmette-Guerin
    Shah, Jay B.
    Kamat, Ashish M.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2013, 40 (02) : 211 - +
12345